Analysts Say U.S. MSOs Trulieve and Curaleaf Are a Buy With Upside of Up to 177% North of the Border, Cannabis 2.0 Sales Could Lift Shares of Valens and VIVO... read more →
According to Analysts, Better Than Expected Earnings Make These 3 Top U.S. Multi-State Operators a Buy Trulieve and Green Thumb Beat Wall Street Estimates After Announcing Q3 Earnings Earlier This... read more →
